"Treatment with GS-5806 reduced the viral load and the severity of clinical disease in a challenge study of healthy adults." (Funded by Gilead Sciences; ClinicalTrials.gov number, NCT01756482.)
Reduced the severity of clinical disease is the same thing that a cure?
I don't think so, right?
NVAX vaccine is ONE DOSE and go home. You're inmune :)
they have a road map, they cannot fight all wars and they don't care if stock goes to "$14 or maybe $24" for just a few days . They want to be at $14 in a steady way.
The problem here is that we think a shareholders and we do what we do .We want to take profits as fast and high as possible.
If $9 is based on 40% probability of success on RSV and flu vaccines ( ended all phases I and about to start phases II ) ..... 100% of success of all phase III.... do the math ... $22-23???
Sentiment: Strong Buy
OK Colkaht. :)
I'm long until market discounts a success in the three phases II for RSV, if market discounts ... of course. About Q2 2015.
One year from now it's easy for me to say that price will be in double digits.
Short term , instead, is a real mess, a caos. I don't know.
BARDA renewal will be a green day , a green week maximum. Over $5.20? well, maybe ...
are you talking about Type C meeting with FDA for starting phase 2 for pregnant women?
Three phases II for RSV HAVE BEEN CONFIRMED to start by Q4